Research programme: HIV vaccines - Immunotech Laboratories

Drug Profile

Research programme: HIV vaccines - Immunotech Laboratories

Alternative Names: Immune therapeutic vaccine-2; Immune therapeutic vaccine-3; Immune therapeutic vaccine-4; Inactivated pepsin fraction HIV vaccine - Immunotech Laboratories; IPF-ITV; IPF-ITV-2; IPF-ITV-3; Irreversible pepsin fraction HIV vaccine - Immunotech Laboratories; ITV-2; ITV-3; ITV-4

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections(In children) in USA (Parenteral)
  • 26 Apr 2013 Immunotech files an IND application with the FDA in US for HIV infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top